ソラスキー医療センターにて、肺がんゲノミクスと革新的な治療法に重点を置く胸部悪性腫瘍の第一人者。
メリムスキー教授は、ソラスキー医療センターの肺がんサービスを率いており、胸部腫瘍学における広範な研究と臨床に注力しています。
Hisar Hospital Intercontinentalにて、肺がん治療（区域切除術）を専門とする。MD Andersonがんセンターを含むトップクラスの医療機関で研修を積む。
ハビエル・センテノ・フォルニエス医師は、メイヨークリニックでの専門的なトレーニングと、Centro Médico Teknonでの_doctor_8374_年以上にわたる外科手術の経験を有しています。
ベルジェ医師は、白内障手術と視覚の神経生理学的メカニズムを専門とし、スポーツ関連の視覚問題に焦点を当てています。
クレペトコ教授はオーストリアにおける肺移植のパイオニアであり、ウィーンの胸部外科の進歩を牽引しています。ニキ・ラウダ氏の移植手術など、数十年にわたる画期的な実績があります。
准教授のユスフ・アチクギョズ医師は、オハイオ州立大学での最先端の腫瘍学の専門知識をアンカラのロクマン・ヘキム大学病院にもたらします。
フォックス医師は、ゾーリンゲンのメディカルセンターにて、化学療法、免疫療法、標的療法の専門知識を持つ肺区域切除術のスペシャリストです。
タフシン・オザトリ准教授は、Istinye Liv大学病院にて肺区域切除術を専門としており、精密な癌治療を提供しています。
低侵襲技術に重点を置くシェンカー教授は、ゾーリンゲン大学病院の外科部長を務め、ロボット支援手術の先駆者として活躍しています。
フェリックス・ドブリトイウ医師は、ポンデラス・アカデミック病院にて低侵襲およびロボット支援胸部外科を専門とし、複雑な肺切除術において豊富な経験を有しています。
セルカン・アレムダル医師は、肺区域切除術における専門的な知識を持ち、複雑な腫瘍症例に対して、正確かつ患者中心のケアを提供することに注力しています。
Medical Park Bahcelievler病院にて肺がん手術を専門とし、精密な区域切除術に注力しています。
ヤイール・バー博士は、シェバ医療センターの癌センターの副所長であり、胸部腫瘍内科医です。進行非小細胞肺癌の治療において、個別化免疫療法および標的療法を専門としています。分子生物学の博士号（PhD）を取得しており、免疫療法耐性に焦点を当てた研究室を主導しています。
ヤーコフ・ローレンス医師は、シェバ医療センターの放射線腫瘍科部長です。精密放射線治療と神経腫瘍学を専門としています。ローレンス医師は、膵臓がんの疼痛管理のための腹腔神経叢ラジオサージェリー（放射線外科）の先駆者です。専門分野における最高の名誉の一つであるFASTROの称号を保持しています。
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
アムル・マフムード・アル・デメリ医師は、シェファ・アル・オルマン病院の胸部外科腫瘍学コンサルタントです。胸部がんの診断と外科的治療を専門としています。アル・デメリ医師は英国王立外科医師会の会員であり、国立がん研究所で外科腫瘍学の博士号を取得しています。
パストラナ医師は、ガレニア病院で精密な胸部手術を専門とする認定外科腫瘍医です。
准教授のCevper Ersozは、Medipol Acibadem地区病院にて、ロボット支援手術や腹腔鏡下手術を含む低侵襲泌尿器科手術を専門としています。
| 順位 | 医師 | 経験 | 適合する方 | 特色 | クリニックと所在地 | 診察 |
|---|---|---|---|---|---|---|
| #1 | 29年の経験 | 肺がんゲノミクス | 精密な肺がん治療のためのゲノムプロファイリングとリキッドバイオプシーに注力。イスラエル肺がん学会の分子腫瘍ボードを主宰し、国家的なゲノムイニシアチブを牽引している。 | イスラエル | から $750 | |
| #2 | 41年の経験 | 肺がんの区域切除術 | 胸部腫瘍学を専門とし、研究において多大な貢献をしている。IASLCのメンバーであり、ソラスキー医療センターの肺がんサービスを統括。 | イスラエル | から $950 | |
| #3 | 20年の経験 | 肺区域切除術 | 世界最高峰のがんセンターの一つであるMD Andersonで研修を受けたがん専門医。肺機能を温存する精密な手術に注力している。 | トルコ | から $100 | |
| #4 | 32年の経験 | 腹腔鏡下肺手術 | メイヨークリニックで培った精密さを低侵襲胸部外科手術にもたらします。最適化された回復プロトコルに関するERAS認定を取得。准教授として外科教育にも積極的に携わっています。 | スペイン | お問い合わせください | |
| #5 | 76年の経験 | 白内障手術とスポーツビジョン | 涙液分泌に関する画期的な研究を行う眼科のリーダー。外科的革新に対する多数の賞を受賞しており、主要な国際学会の会員でもあります。 | スペイン | お問い合わせください | |
| #6 | 48年の経験 | 複雑な肺区域切除術 | 画期的な症例を通じてオーストリアの肺移植プログラムを先導。ウィーン医科大学にて、低侵襲技術を用いた胸部外科の革新を牽引している。 | オーストリア | お問い合わせください | |
| #7 | 10年の経験 | 進行肺がんの症例 | 第III相臨床試験の研究経験を患者ケアに活かしている。オハイオ州立大学で腫瘍内科の訓練を受けたASCO会員。 | トルコ | お問い合わせください | |
| #8 | 14年の経験 | 先進的な治療法を用いた肺区域切除術 | 肺区域切除術における化学療法、免疫療法、標的療法の専門家。遺伝学を専門とするBKZゾーリンゲンの主任医師。 | ドイツ | お問い合わせください | |
| #9 | 2016年の経験 | 肺区域切除術 | 精密な癌治療に重点を置いた肺区域切除術の専門家。トルコ全土で豊富な腫瘍学の経験を持つ准教授。 | トルコ | お問い合わせください | |
| #10 | 19年の経験 | 低侵襲肺手術 | ロボット手術の進歩におけるパイオニアであり、最先端機器への多額の投資を確保。ドイツ初の認定大腸がんセンターを率いる。 | ドイツ | お問い合わせください |